CRL vs ZTS · rev $2.00B vs P/E 25, rev $2.47B
Charles River Laboratories (CRL) versus Zoetis Inc (ZTS) — a side-by-side from cached financials, not a winner call.
Charles River Laboratories (CRL) is a diagnostics & research company listed on US.
Zoetis Inc (ZTS) is a drug manufacturers - specialty & generic company listed on US.
Latest reported CRL revenue for 2026-06-27 was $2.00B. Net income was -$16.3M. CRL currently screens at market cap $7.78B.
Latest reported ZTS revenue for 2026-06-30 was $2.47B. Net income was $691.0M. Revenue was up 9.1% from 2026-03-31 to 2026-06-30. ZTS currently screens at market cap $64.65B and trailing P/E 24.9.
CRL currently screens at market cap $7.78B. ZTS currently screens at market cap $64.65B and trailing P/E 24.9.
Not investment advice. Open the CRL and ZTS stock pages for the full models.
Not investment advice.